Mannkind Corporation has signed a collaboration and license agreement with Receptor Life Sciences, Inc. to develop multiple inhaled therapeutic products for conditions that like chronic pain, neurologic diseases, and inflammatory disorders.
As per terms of the agreement, MannKind will work with Receptor to develop inhaled formulations of certain undisclosed compounds and will perform initial formulation studies. On the other hand, Receptor will be responsible for manufacturing and commercialization. The companies will collaborate on the development of the products, with development costs being financed by Receptor.
MannKind is eligible to receive up to $102.25 million as development and commercialization milestones, along with mid-single to low double-digit royalties, on net product sales.
Receptor Life Sciences Website: www.receptorlife.com
THAT’S ALL WE KNOW FOR NOW!
There is a lot of speculation about Receptor Life Sciences.